Sky Medical Technology Ltd., an investee company within the Deepbridge Technology Growth EIS portfolio, announced further U.S. Food and Drug Administration (FDA) 510(k) clearance to market the new (W3) geko™ device variant, for increasing microcirculatory blood flow in lower limb soft tissue of patients with venous insufficiency and/or ischemia.
Venous insufficiency and ischemia relate to reduced blood flow in the veins and arteries, which can lead to lower extremity oedema, skin changes and discomfort. Each year nearly $500 million is used in the care of chronic venous insufficiency patients.*
Bernard Ross, CEO and Founder, Sky Medical Technology Ltd. commented:
"Achieving this latest 510(k) clearance for the geko™ device (W3) establishes Sky's position as a leading innovator in MedTech dedicated to improving patient outcomes. Conditions such as venous insufficiency and ischemia are therapy areas sorely in need of innovation, and we are pleased to contribute to improvements in this care pathway that make recovery quicker, simpler and more comfortable."
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).
*Source: (Patel SK et al. Venous Insufficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Aug 4./https://www.ncbi.nlm.nih.gov/books/NBK430975/)